Concepts for Disposables in Biopharmaceutical Manufacture

  • Joachim K. Walter
  • Uwe Gottschalk
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume XI)


The biopharmaceutical manufacturing industry has had a long relationship with stainless steel, and even a decade ago it would have been hard to imagine the industry embracing a new concept that could make stainless steel redundant. Even so, the tide is turning, and disposable concepts are on the rise (Sinclair and Monge 2004). Disposable equipment became popular for upstream production in the 1990s, with the advent of “single-use” media bags and bioreactors, and the use of disposable capsules for sterile filtration (Meyeroltmanns et al. 2005). Over the next few years, disposable concepts also began to appear in downstream processing. Initially, this was restricted to buffer bags and devices for normal flow filtration, including virus filtration and guard filters for chromatographic columns, but gradually more complex concepts have been introduced, including disposable devices for tangential flow filtration and chromatography (Walter 1998; Ransohoff 2004; Gottschalk 2006). The current importance of disposable concepts in downstream processing was demonstrated in a recent industry survey, in which 37% of respondents considered cost-effective disposables to be important for addressing downstream process capacity issues in 2006, when compared to 24% in 2005 (BioPlan BioProcess Technology Consultants 2005, 2006).


Facility Layout Tangential Flow Filtration Upstream Production Membrane Adsorber Disposable Device 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Baldi L, Muller N, Picasso S, Jacquet R, Girard P, Thanh HP, Derow E, Wurm FM (2005) Transient gene expression in suspension HEK-293 cells: application to large-scale protein production. Biotechnol Prog 21:148–153PubMedCrossRefGoogle Scholar
  2. BioPlan BioProcess Technology Consultants (2005) Third Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, 2005Google Scholar
  3. BioPlan BioProcess Technology Consultants (2006) Fourth Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and ProductionGoogle Scholar
  4. CPMP (1996) Note for guidance on virus validation studies. The design, continuation and interpretation of studies validating the inactivation and removal of viruses. CPMP/BWP/268/95Google Scholar
  5. Curling J (2007) Process chromatography: five decades of innovation. BioPharm Int (Suppl):10–19Google Scholar
  6. De Jesusa MJ, Girard P, Michaela Bourgeois M, Baumgartner G, Jacko B, Amstutz H, Wurm FM (2004) TubeSpin satellites: a fast track approach for process development with animal cells using shaking technology. Biochem Eng J 17:217–223CrossRefGoogle Scholar
  7. Desai MA, Rayner M, Burns M, Bermingham D (2000) Application of chromatography in the downstream processing of biomolecules. In: Desai MA (ed) Downstream processing of proteins: methods and protocols. Methods in , vol 9. pp 73–94Google Scholar
  8. DiBlasi K, Jornitz MW, Gottschalk U, Priebe PM (2006) Disposable biopharmaceutical processes – myth or reality? BioPharm Int 2–10Google Scholar
  9. European Commission Enterprise Directorate General (2001) Working Party on Control of Medicines and Inspections. EU Guide to Good Manufacturing Practice, vol 4, Annex 15, July 2001, Cleaning Validation (Source:
  10. FDA (1987) Guideline on sterile drug products produced by aseptic processing. FDA, Rockville, MDGoogle Scholar
  11. FDA (2004) Equipment cleaning and maintenance. Code of Federal Regulations (CFR) Part 211.67 Title 21 Rev. 25 May 2004, FDA, Rockville, MD (Source:
  12. FDA (2006) Guide to inspections validation of cleaning processes. FDA, Rockville, MD (Source:
  13. Gebauer K, Thommes J, Kula M (1997) Plasma protein fractionation with advanced membrane adsorbents. Biotechnol Bioeng 54:181–189PubMedCrossRefGoogle Scholar
  14. Gottschalk U (2005) New and unknown challenges facing biomanufacturing. BioPharm Int 18:24–28Google Scholar
  15. Gottschalk U (2006) The Renaissance of protein purification. Biopharm Intl June (suppl):8–9Google Scholar
  16. Gottschalk U (2008) Biochromatography in antibody manufacturing: the good, the bad and the ugly. Biotechnol Prog (in press)Google Scholar
  17. Gottschalk U, Lamproye A, Zhou J, Sinclair A, Reif O-W (2006) An integrated platform for robust virus and contaminant removal in biomanufacturing. Recovery of Biological Products XII, Phoenix, Arizona, April 2–7, 2006Google Scholar
  18. Immelmann A, Kellings K, Stamm O, Tarrach K (2005) Validation and quality procedures for virus and prion removal in biopharmaceuticals. BioProcess Int 3:38–45Google Scholar
  19. Lim JAC, Sinclair A, Kim DS, Gottschalk U (2007) Economic benefits of single-use membrane chromatography in polishing. A cost of goods model. BioProcess Int 5:60–64Google Scholar
  20. Meyeroltmanns F, Schmitz J, Nazlee M (2005) Disposable bioprocess components and single-use concepts for optimized process economy in biopharmaceutical production. Bioprocess Int 3:60–66Google Scholar
  21. Mora J, Sinclair A, Delmdahl N, Gottschalk U (2006) Disposable membrane chromatography. Performance analysis and economic cost model. Bioprocess Int 4(Suppl):38–43Google Scholar
  22. Muller N, Derouazi M, Van Tilborgh F, Wulhfard S, Hacker DL, Jordan M, Wurm FM (2007) Scalable transient gene expression in Chinese hamster ovary cells in instrumented and non-instrumented cultivation systems. Biotechnol Lett 29:703–711PubMedCrossRefGoogle Scholar
  23. Prashad M, Tarrach K (2006) Depth filtration aspects for the clarification of CHO cell derived biopharmaceutical feed streams. FISE 9:28–30Google Scholar
  24. Ransohoff T (2004) Disposable chromatography: current capabilities and future possibilities. BPD North Carolina Biotechnology Center, 18 Nov 2004Google Scholar
  25. Reif OW, Solkner P, Rupp J (1996) Analysis and evaluation of filter cartridge extractables for validation of pharmaceutical downstream processing. J Pharm Sci Technol 50:399–407Google Scholar
  26. Sinclair A, Monge M (2002) Quantitative economic evaluation of single use disposables in bioprocessing. Pharm Eng 22:20–34Google Scholar
  27. Sinclair A, Monge M (2004) Biomanufacturing for the 21st century: designing a concept facility based on single-use systems. BioProcess Int 2:26–31Google Scholar
  28. Stettler M, Jaccard N, Hacker D, De Jesus M, Wurm FM, Jordan M (2006) New disposable tubes for rapid and precise biomass assessment for suspension cultures of mammalian cells. Biotechnol Bioeng 95:1228–1233PubMedCrossRefGoogle Scholar
  29. Stone TE, Goel V, Leszczak J (1994) Methodology for analysis of extractables: a model stream approach. J Pharm Technol 18:116–121Google Scholar
  30. Walter JK (1998) Strategies and considerations for advanced economy in downstream processing of biopharmaceutical proteins. In: Subramanian G (ed) Bioseparation and bioprocessing. Processing, quality and characterization, economics, safety and hygiene. Wiley VCH, New York, pp 447–460CrossRefGoogle Scholar
  31. Weitzmann KH (1997) The use of model solvents for evaluating extractables from filters used to process pharmaceutical products. Pharm Technol 21:73–79Google Scholar
  32. Zhou J (2006) Disposable anionic membrane chromatography. IBC Technology Transfer for Biopharmaceuticals, Carlsbad, CA 2006Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2010

Authors and Affiliations

  1. 1.emergene AGTeufenSwitzerland
  2. 2.Sartorius-Stedim Biotech GmbHGöttingenGermany

Personalised recommendations